UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE DETERMINATION OF BILASTINE USING EXPERIMENTAL DESIGN FOR ROBUSTNESS by Tassinari da Silva, Andressa et al.
Drug Analytical Research 
Drug Anal Res, 2017; 01, n.2, 38-43 
 
38 
 
UV Spectrophotometric method for quantitative determination of Bilastine using 
experimental design for robustness 
 
 Andressa Tassinari da Silva a; Gabriela Rossi Brabo a, Isadora Dias Marques a, b; Lisiane Bajerski a; 
Marcelo Donadel Malesuik a, b; Clésio Soldateli Paim a, b,* 
 
a Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade; Curso de Farmácia; Universidade Federal do 
Pampa (UNIPAMPA – Campus Uruguaiana-RS), BR 472 – Km 585, CEP 97500-970, Uruguaiana (RS), Brasil. 
 
b Programa de Pós-Graduação em Ciências Farmacêuticas, Curso de Farmácia, Universidade Federal do Pampa 
(UNIPAMPA – Campus Uruguaiana-RS), BR 472 – Km 585, CEP 97500-970, Uruguaiana (RS), Brasil. 
 
Corresponding author e-mail: clesiopaim@unipampa.edu.br 
 
Bilastine is a novel nonsedative H1-receptor antagonist, which may be used for the symptomatic treatment of chronic 
idiopathic urticaria (CU). This study describes the validation of an UV spectrophotometric method for quantitative 
determination of bilastine in tablets using 0.1 mol L-1 HCl as solvent. The method was specific, linear, precise, exact and 
robust at 210 nm, confirming that the method is fast and useful to the routine quality control of bilastine in tablets. The 
validate method was compared to liquid chromatography (HPLC), which was previously developed and validated to the 
same drug, and no significative difference between the methods using Student´s t test was found to bilastine quantitation. 
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Introduction 
 
Bilastine (Figure 1) is a novel nonsedative 
H1-receptor antagonist, which may be used for 
the symptomatic treatment of chronic 
idiopathic urticaria and allergic 
rhinoconjunctivitis (1).  
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 1 Chemical structure of bilastine. 
 
Pharmacological studies have shown that 
the drug is highly selective for the H1 receptor 
in both in vivo and in vitro studies, and with no 
apparent affinity for other receptors. The 
absorption of bilastine is fast, linear and dose-
proportional; it appears to be safe and well 
tolerated at all doses levels in healthy 
population (2).  
Although there are some papers describing 
the determination of bilastine in 
pharmacokinetic studies by LC-fluorescence 
detection and LC-MS-MS (3, 4) and by 
hydrophilic interaction liquid chromatographic 
method (HILIC) (5), there are no studies 
describing quantification methods by UV 
spectrophotometry. Then the main objective of 
this study was to develop a simple, fast and low 
cost UV spectrophotometry method, without 
extraction process, derivatization process, and 
evaporation step, providing decrease in time 
and error in the quantitative determination of 
bilastine in tablets.  
The method described in this study was 
validated through the evaluation of the 
following analytical parameters: specificity, 
linearity, precision (repeatability and 
intermediate precision), accuracy and 
robustness (6,7). Experimental design was used 
to evaluate method robustness (8). Besides, the 
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statistical comparison of the precision results 
with those obtained from the HPLC (previously 
validated by the same research group) was 
presented to show the suitability of the 
developed method. 
 
Experimental 
 
Reagents and Chemicals 
 
Bilastine chemical reference standard 
(CRS) (99.7%) was acquired from TRC 
(Toronto, Ontario, Canada). Alektos® (Takeda, 
São Paulo, Brazil), composed of a 20 mg 
bilastine, was purchased in the market. The 
excipients contained in the dosage form 
(microcrystalline cellulose, sodium starch 
glycolate, magnesium stearate and colloidal 
silicon dioxide) were all pharmaceutical grades 
and were acquired from different suppliers. All 
chemicals and solvents used were of analytical 
grade. Methanol was purchased from Avantor® 
(J.T.BAKER, Center Valley, PA, USA) and 
Neon® (Suzano, SP, Brazil). Acetonitrile 
HPLC grade was purchased from Avantor® 
(J.T.BAKER, Center Valley, PA, USA). 
Purified water was prepared using Milli-Q 
Plus® (Millipore, Bedford, USA). 
 
Instrumentation and Conditions 
 
Spectral and absorbance measurements 
were performed with an UV-Vis Perkin-Elmer, 
model Lambda 35 using 10 mm quartz cells and 
detection at 210 nm.  
A Shimadzu Prominence® liquid 
chromatograph (Kyoto, Japan) LC Solution V. 
1.24 SP1 manager system software was used. 
The chromatographic separation was 
performed in a Shim-pack® RP-18 column (150 
x 4.6 mm I.D., 5 µm, Shimadzu, Kyoto, Japan). 
The mobile phase comprising a mixture of 0.3% 
triethylamine (pH adjusted to 6.0 with 20% 
formic acid) and acetonitrile (55:45, v/v) at a 
flow-rate of 1.0 mL min-1 with isocratic elution 
at 25 °C. The injection volume was 20 µL for 
both reference substance and drug product 
solutions and the run time was 5 min. Bilastine 
was determined by UV detection at 207 nm 
using photodiode-array. 
Preparation of RS and sample solutions 
 
Bilastine CRS was accurately weighed and 
dissolved in a 100 mL volumetric flask with 0.1 
mol L-1 HCl to produce a concentration of 100.0 
µg mL-1. This solution was diluted 
appropriately in the same diluent to yield a final 
concentration of 10.0 µg mL-1. To prepare a 
sample solution, twenty tablets of Alektos® 
were weighed and finely powdered. A quantity 
equivalent to 5.0 mg of the bilastine was 
transferred into a 50 mL volumetric flask with 
30 mL of 0.1 mol L-1 HCl and kept in an 
ultrasonic bath for 30 min. The volume was 
completed with the same diluent, filtered and an 
aliquot of this solution was volumetrically 
diluted to yield a final concentration of 10.0 µg 
mL-1. The stability of bilastine CRS and 
sample solutions in 0.1 mol L-1 HCl was 
evaluated at room temperature (23±1°C) during 
24 h using the HPLC method. The stability of 
these solutions was verified by observing any 
change in the chromatographic pattern and in 
the decrease of the response of the peak (area), 
which can indicate the degradation of the 
solutions. 
 
Method validation 
 
Different solvents were investigated to 
develop a suitable UV spectrophotometric 
method for the analysis of bilastine in tablets. 
For selection of solvent the criteria employed 
was the easiness of sample preparation, 
solubility and stability of the drug, cost of 
solvent, toxicity and applicability of the 
method. 
The evaluation of the method specificity 
was performed by preparing a placebo 
containing the same excipients of the 
commercial product. A quantity of excipients 
contained in the equivalent to 5.0 mg of the 
bilastine was transferred into a 50 mL 
volumetric flask with 30 mL of 0.1 mol L-1 HCl 
and kept in an ultrasonic bath for 30 min. The 
volume was completed with the same diluent, 
filtered and 1.0 mL of this solution was 
transferred into a 10 mL volumetric flask using 
0.1 mol L-1 HCl. 
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Three calibration curves were prepared 
with six concentrations of bilastine CRS at 210 
nm (3.0, 4.0, 5.0, 10.0, 15.0 and 20.0 µg mL-1) 
to evaluate the linearity and for each 
concentration the solutions were prepared in 
triplicate. The obtained absorbances were 
plotted against the respective concentrations of 
drug to obtain the analytical curves. The 
calculation of the regression line was employed 
by the method of least squares and the curves 
were validated by means of the analysis of 
variance (ANOVA). 
The determination of precision was done 
through six sample solutions at the same 
concentrations (10.0 g mL-1) under the same 
experimental conditions in the same day for 
intra-day precision (repeatability) and on three 
different days for inter-day precision 
(intermediate precision). The relative standard 
deviations (RSD) were determined. 
Accuracy was calculated as percentage 
recovery by adding known amounts of bilastine 
CRS to synthetic mixtures of the formulation 
excipients. The analyses were done in three 
replicates in each concentration (3.0, 10.0, and 
20.0 g mL-1).  
The robustness tests using experimental 
design in the bilastine assay provided an 
effective approach as part of the method 
validation. Robustness testing was performed 
in order to evaluate the susceptibility of 
measurements due to deliberate variations in 
analytical conditions. The factors were 
examined in an experimental design of 8 
experiments, which was selected as a function 
of the number of factors to investigate (8). This 
designs applied, so-called two-level screening 
designs, allows screening a relatively large 
number of factors in a relatively small number 
of experiments.  
The factors and the levels investigated in 
robustness evaluation are summarized in Table 
1. The construction of the experimental designs 
with 8 experiments was performed in 
accordance to Plackett–Burman described in 
Heyden and collaborators (8). After 
determination of the number of real factors to 
be examined, the remaining columns in the 
design were defined as dummy factors, which 
is an imaginary factor that has no physical 
meaning. A half-normal probability plot for the 
effects in combination with the dummy factors 
was used to estimate the error and identify 
significant effects. 
 
Table 1 Factors and levels investigated in the robustness test. 
Factors Nominal Level (-1) Level (+1) 
Solvent brand J.T.Baker® Neon® J.T.Baker® 
Time of Shaking 
(ultrasonic bath) (min.) 30 28 32 
Wavelength (nm) 210  208 212 
 
For each factor its resulting effect was 
calculated according to the Equation 1: 
 
2/
)(
2/
)(
N
Y
N
Y
Ex
   (Equation 1) 
 
Where: EX is the effect of X on response Y 
(bilastine concentration); Y(+) and Y(-) are 
the sums of the responses where X is at the 
extreme levels (+) and (-), respectively, and N 
is the number of experiments of the design. 
The effect of the estimate experimental 
error (SE)e allows concluding what is 
significant from dummy factors (Equation 2). 
This value was used to perform the statistical 
test. 
error
dummy
e n
E
SE 
2
)(  (Equation 2) 
 
Where: E2error is the sum of squares of the 
nerror dummy. 
 
The statistical interpretation provides to the 
user a numerical limit value that allows 
defining what is significant and what is not. 
This limit value to identify statistically 
significant effects is usually derived from the t-
test statistic, in accordance to the Equation 3: 
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An effect is considered significant at a 
given  level if t calculated > t critical (8).  
 
Methods comparison 
 
In order to compare the developed UV 
spectrophotometry method at 210 nm with well 
characterized procedure (HPLC method 
previously validated), the precision results of 
these methods were statistically analyzed using 
Student´s t test, which indicates if there is 
significant difference between the methods at 
5% significant level. 
 
Results and Discussion 
 
The UV-VIS method is very used in the 
quality control of pharmaceutical products due 
to the potential of the great majority of the 
drugs of absorbing energy in these 
wavelengths. The development of a simple, 
rapid, sensitive, and accurate UV 
spectrophotometric method for the routine 
quantitative determination of samples reduces 
unnecessary tedious sample preparations and 
the cost of analysis (9). 
Considering the solubility and stability, the 
following solvents were used as diluent of the 
bilastine in the CRS and the sample solutions: 
methanol and 0.1 mol L-1 HCl. The stability of 
bilastine in acid solution was evaluated to 
verify if any spontaneous degradation occurs 
when the samples were prepared. The studies 
performed by HPLC method showed the 
stability of the drug in acid solution by 24 h. 
Besides that, the 0.1 mol L-1 HCl is considered 
less toxic than methanol. Then the utilization of 
this solvent was evaluated to perform the 
spectrophotometric method validation (Figure 
2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 UV-absorption spectra of 10.0 g mL-1 concentration of bilastine in 
tablets (a) and bilastine CRS solutions (b) in 0.1mol L-1 HCl. 
 
The specificity test demonstrated that there 
was not interference of the excipients in the 
drug determination at 210 nm using 0.1 mol L-
1 HCl as solvent.  
Linearity was observed over the 
concentrations range of 3.0 to 30.0 µg mL-1 at 
210 nm with significantly high value of 
correlation coefficient (r=0.9998). The validity 
of the assay was verified by means of ANOVA 
and according to it, there are linear regression 
and there are not deviation from linearity ( = 
0.05, Table 2). 
 
 Table 2 Statistical data of the regression equations to analysis of bilastine. 
Regression analysis  210 nm 
Linearity range (g mL-1) 3 – 20 
Slope 0.0525 
Intercept -0.0042 
Correlation coefficient (r) 0.9998 
Lack of fitting (critical F-value)a 0.21 (3.26) 
Linear regression F-value (critical F-
value)a 6460.6 (3.11) 
a Theoretical value of F is based on one-way ANOVA test at  = 0.05 level of significance. 
The Student’s t-test was performed to 
verify the significance of the experimental 
intercept in the regression equation. According 
to the results, it is not significantly different 
from the theoretical zero value with a 
significance level of 5% (p > 0.05). 
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The experimental values obtained for the 
determination of the analytical method 
precision (repeatability and intermediary 
precision) are presented in Table 3. The low 
relative standard deviations (RSD) obtained for 
the repeatability and intermediary precision 
showed the good precision of the analytical 
method. 
 
Table 3 Repeatability values obtained for bilastine in tablets by UV 
spectrophotometry at 210 nm. 
 
Sample (n) 
Repeatability 
Day 1 Day 2 Day 3a 
1 
99.55 101.93 99.74 
2 
101.26 100.32 99.11 
3 
103.30 99.05 97.39 
4 
103.48 101.95 99.27 
5 
102.45 102.98 99.86 
6 
102.12 103.78 100.25 
Mean (%) 102.03 101.67 99.27 
RSD (%) 1.43 1.70 1.01 
Inter-day - Mean values % (n=18) 
Mean (%)  100.99  
RSD (%)  1.82  
aAnalystB     
The accuracy was calculated in relation of 
the percentage of recovery of the known added 
amount of bilastine CRS to the excipients 
solution. The accuracy of the method ranged 
from 99.53 to 100.54%. These values showed 
the good accuracy of the purposed method. 
The results of the robustness experiments 
are presented in Table 4. They are expressed in 
percentage of bilastine in the sample solution 
calculated using standard solution in the same 
experimental condition. The effects of the 
factors in analysis, the error estimated starting 
from the factors dummy and the value of t - 
calculated are also showed in Table 4. The 
analysis of the results of the robustness study 
demonstrated that the factors in analysis did not 
present significant effect on the quantitation of 
the drug, indicating the robustness of the UV 
spectrophotometric method in the analytical 
conditions.  
 
Table 4 The selected Plackett-Burman design, results of the experiments and 
effects (Ex) of the factors. 
 
 
 
 
 
 
 
 
 
 
 
The statistical comparison between the UV 
spectrophotometry at 210 nm and HPLC 
method was performed through Student´s t test 
using the mean experimental values, obtained 
in the precision of the methods (Table 5). The 
test did not show statistical difference between 
the techniques (tcalc = 0.0011 < tcrit = 1.691, p > 
0.05), showing also the capacity of this 
developed method to quantify the drug bilastine 
in tablets with accuracy and precision.  
 
Table 5 Statistical analysis between HPLC and UV methods. 
 
HPLC assay (%)  UV assay (%) 
Mean (%) (n=18) 99.21 100.99 
SD  1.90 1.84 
RSD 1.91 1.82 
Student s´ t test                                              0.0011  ( p > 
0.05) 
T critical  1.69  
 
 
Conclusions 
 
An HPLC-UV method was developed for 
determining the encapsulation efficiency of 
zidovudine in nanoparticles. This 
chromatographic method was considered 
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simple and rapid, since the preparation of the 
samples did not involve complex and prolonged 
processes.  Furthermore, the HPLC-UV method 
was validated in terms of selectivity, stability, 
linearity, limits of quantitation and detection, 
precision, accuracy and robustness. Finally, it 
provided unequivocal determination of the 
amount of zidovudine in nanoparticule 
formulation which may be applied to stability 
or quality control.  
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